The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram

被引:38
作者
Kuan, Wei-Li [1 ]
Zhao, Jing-Wei [1 ]
Barker, Roger A. [1 ,2 ,3 ]
机构
[1] Cambridge Ctr Brain Repair, Cambridge CB2 2PY, England
[2] Addenbrookes Hosp, Dept Neurol, Cambridge CB2 2QQ, England
[3] Edith Cowan Univ, Perth, WA, Australia
基金
英国医学研究理事会;
关键词
Parkinson's disease; levodpa-induced dyskinesia; elevated plus maze; open field; abnormal involuntary movements; DARPP-32; Cdk5; 5-HT1b;
D O I
10.1007/s00213-007-1030-6
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Introduction Levodopa-induced dyskinesia (LID) is an inevitable complication of the long-term treatment of Parkinson's disease (PD) with levodopa. In a rat model of LID, we observed that animals of almost identical genetic but slightly different environmental backgrounds displayed a very different profile in terms of their development and severity of LID. Materials and methods We hypothesised that this heterogeneity can be attributed to different levels of anxiety in individual animals. We evaluated the basal anxiety level of rats in this study using the elevated plus maze (EPM), open field (OF) test, and plasma corticosterone level. These animals then received unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway after which they were primed to develop LID. Finally, we manipulated the anxiety level of these animals by citalopram treatment over a 9-week period before they were killed. Results Although we could not establish an association between the anxiety level of rats with either the onset or severity of LID, our results showed that citalopram was able to mediate a partial alleviation in LID after chronic treatment, and the extent of recovery was negatively correlated to the anxiety measures of individual animals. Furthermore, this citalopram-mediated LID recovery appeared to be independent of any changes in striatal cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) and cyclin-dependent kinase 5 (Cdk5) system, in contrast to our previous studies with fetal ventral mesencephalon transplants. However, chronic citalopram treatment almost completely abolished the expression of serotonin receptor 1B (5HT1B) in the striatum in animals exhibiting LID recovery. Conclusions These results indicate a novel association of serotonin receptors in the development of LID and contributes to the evidence that the serotonergic system may play an important role in such movements.
引用
收藏
页码:279 / 293
页数:15
相关论文
共 40 条
[1]   Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia [J].
Aubert, I ;
Guigoni, C ;
Håkansson, K ;
Li, Q ;
Dovero, S ;
Barthe, N ;
Bioulac, BH ;
Gross, CE ;
Fisone, G ;
Bloch, B ;
Bezard, E .
ANNALS OF NEUROLOGY, 2005, 57 (01) :17-26
[2]   Therapeutic monitoring of psychotropic drugs -: An outline of the AGNP-TDM Expert Group Consensus Guideline [J].
Baumann, P ;
Hiemke, C ;
Ulrich, S ;
Rao, GML ;
Eckermann, G ;
Gerlach, M ;
Kuss, HJ ;
Laux, G ;
Müller-Oerlinghausen, B ;
Rieder, P ;
Zernig, G .
THERAPEUTIC DRUG MONITORING, 2004, 26 (02) :167-170
[3]   Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies [J].
Bezard, E ;
Brotchie, JM ;
Gross, CE .
NATURE REVIEWS NEUROSCIENCE, 2001, 2 (08) :577-588
[4]   Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons [J].
Bibb, JA ;
Snyder, GL ;
Nishi, A ;
Yan, Z ;
Meijer, L ;
Fienberg, AA ;
Tsai, LH ;
Kwon, YT ;
Girault, JA ;
Czernik, AJ ;
Huganir, RL ;
Hemmings, HC ;
Nairn, AC ;
Greengard, P .
NATURE, 1999, 402 (6762) :669-671
[5]   Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models [J].
Bibbiani, F ;
Oh, JD ;
Chase, TN .
NEUROLOGY, 2001, 57 (10) :1829-1834
[6]   Emotional changes related to age in rats - a behavioral analysis [J].
Boguszewski, P ;
Zagrodzka, J .
BEHAVIOURAL BRAIN RESEARCH, 2002, 133 (02) :323-332
[7]   EFFECT OF CHRONIC ANTIDEPRESSANT TREATMENT ON 5-HT1B PRESYNAPTIC HETERORECEPTORS INHIBITING ACETYLCHOLINE-RELEASE [J].
BOLANOSJIMENEZ, F ;
DECASTRO, RM ;
FILLION, G .
NEUROPHARMACOLOGY, 1994, 33 (01) :77-81
[8]   BUSPIRONE IN LEVODOPA-INDUCED DYSKINESIAS [J].
BONIFATI, V ;
FABRIZIO, E ;
CIPRIANI, R ;
VANACORE, N ;
MECO, G .
CLINICAL NEUROPHARMACOLOGY, 1994, 17 (01) :73-82
[9]   Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in Parkinsonian rats [J].
Carta, Manolo ;
Carlsson, Thomas ;
Kirik, Deniz ;
Bjorklund, Anders .
BRAIN, 2007, 130 :1819-1833
[10]   Acute stress-induced facilitation of the hypothalamic-pituitary-adrenal axis: Evidence for the roles of stressor duration and serotonin [J].
Cassano, WJ ;
D'mello, AP .
NEUROENDOCRINOLOGY, 2001, 74 (03) :167-177